metricas
covid
Buscar en
Revista Colombiana de Psiquiatría
Toda la web
Inicio Revista Colombiana de Psiquiatría Miocarditis por clozapina: reporte de caso y revisión de tema
Journal Information
Vol. 40. Issue 1.
Pages 170-182 (March 2011)
Share
Share
Download PDF
More article options
Vol. 40. Issue 1.
Pages 170-182 (March 2011)
Reporte de caso
Full text access
Miocarditis por clozapina: reporte de caso y revisión de tema
Myocarditis Due to Clozapine: Case Report and Topic Review
Visits
3614
Jhon Jairo Castañeda Ramírez1,
Corresponding author
pecosjhon@hotmail.com

Correspondencia: Jhon Jairo Castañeda Ramírez, Carrera 7 No. 7-65, Cartago, Valle del Cauca
, José Luis Cardona Deaza2, Harold Miranda Rosero3, Jairo Franco Londoño4
1 Médico. Residente II de Psiquiatría, Universidad Tecnológica de Pereira. Pereira, Colombia
2 Médico patólogo. Profesor, Facultad de Medicina, Universidad Tecnológica de Pereira. Pereira, Colombia
3 Médico internista. Profesor, Posgrado de Medicina Interna, Facultad de Medicina, Universidad Tecnológica de Pereira. Pereira, Colombia
4 Médico psiquiatra forense. Profesor, Posgrado de Psiquiatría, Facultad de Medicina, Universidad Tecnológica de Pereira. Instituto Nacional de Medicina Legal y Ciencias Forenses. Pereira, Colombia
This item has received
Article information
Resumen
Introducción

La miocarditis es definida como la inflamación del músculo cardiaco. A pesar de que existen síntomas que pueden ayudar a realizar su diagnóstico, el paciente puede encontrarse asintomático o debutar con muerte súbita. La clozapina es un medicamento indicado para el tratamiento de la esquizofrenia refractaria, el cual puede producir cardiopatías.

Objetivo

Presentar el caso de un paciente de 20 años, quién falleció debido a una miocarditis por clozapina.

Método

Reporte de caso.

Resultados

Se describe un caso asintomático y fatal de miocarditis por clozapina; se presentan las placas histológicas de miocardio con infiltrado eosinofílico, característico de la entidad.

Discusión

Se describen las características de la entidad y la forma de realizar su diagnóstico.

Conclusión

Aunque la miocarditis por clozapina es bastante rara (prevalencia: del 0,015% al 0,188%), puede producirse en mayor medida durante las primeras 8 semanas de tratamiento, período durante el cual debe investigarse de manera activa.

Palabras clave:
Miocarditis
hipersensibilidad
clozapina
muerte súbita
Abstract
Introduction

Myocarditis is a heart muscle inflammation. There are signs that can help make the diagnosis but, the patient may be asymptomatic or presented with sudden death. Clozapine is indicated for the treatment of refractory schizophrenia, it may cause cardiomyopathies.

Objective

To report the case of a 20-year-old who died of myocarditis due to clozapine.

Methods

Case report.

Results

We describe an asymptomatic case of fatal myocarditis due to clozapine, and we show histological slides of the heart with characteristic eosinophilic infiltration.

Discussion

We discuss the manifestations of the entity and how to diagnose it.

Conclusions

Although clozapine myocarditis is rare (prevalence: 0,015% – 0,188%). It may occur within 8 weeks of treatment, time which should be actively investigated.

Key words:
Myocarditis
hypersensitivity
clozapine
sudden death
Full text is only aviable in PDF
Referencias
[1]
P Wentworth, LA Jentz, AE Croal.
Analysis of sudden unexpected death in southern Ontario, with emphasis on myocarditis.
Can Med Assoc J, 120 (1979), pp. 676-680
[2]
M Grgas, CF Washburn Jr, CF Caley.
Clozapine-induced myocarditis: 2 case reports.
J Clin Psychopharmacol, 30 (2010), pp. 91-92
[3]
SJ Haas, R Hill, H Krum, et al.
Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003.
Drug Saf, 30 (2007), pp. 47-57
[4]
DB Merrill, SE Ahmari, JM Bradford, et al.
Myocarditis during clozapine treatment.
Am J Psychiatry, 163 (2006), pp. 204-208
[5]
JL Whitton, R Feuer.
Myocarditis, microbes and autoimmunity.
Autoimmunity, 37 (2004), pp. 375-386
[6]
LT Cooper Jr.
Myocarditis.
N Engl J Med, 360 (2009), pp. 1526-1538
[7]
GM Felker, RE Thompson, JM Hare, et al.
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.
N Engl J Med, 342 (2000), pp. 1077-1084
[8]
ED Moloney, JJ Egan, P Kelly, et al.
Transplantation for myocarditis: a controversy revisited.
J Heart Lung Transplant, 24 (2005), pp. 1103-1110
[9]
RE Eckart, SL Scoville, CL Campbell, et al.
Sudden death in young adults: a 25-year review of autopsies in military recruits.
Ann Intern Med, 141 (2004), pp. 829-834
[10]
C Basso, F Calabrese, D Corrado, et al.
Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings.
Cardiovasc Res, 50 (2001), pp. 290-300
[11]
Y Drory, Y Turetz, Y Hiss, et al.
Sudden unexpected death in persons less than 40 years of age.
Am J Cardiol, 68 (1991), pp. 1388-1392
[12]
HT Aretz.
Myocarditis: the Dallas criteria.
Hum Pathol, 18 (1987), pp. 619-624
[13]
JW Magnani, GW Dec.
Myocarditis: current trends in diagnosis and treatment.
Circulation, 113 (2006), pp. 876-890
[14]
C Baboonian, T Treasure.
Meta-analysis of the association of enteroviruses with human heart disease.
Heart, 78 (1997), pp. 539-543
[15]
NE Bowles, J Ni, DL Kearney, et al.
Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults.
J Am Coll Cardiol, 42 (2003), pp. 466-472
[16]
AP Burke, J Saenger, F Mullick, et al.
Hypersensitivity myocarditis.
Arch Pathol Lab Med, 115 (1991), pp. 764-769
[17]
JJ Fenoglio Jr, HA McAllister Jr, FG Mullick.
Drug related myocarditis, I: hypersensitivity myocarditis.
Hum Pathol, 12 (1981), pp. 900-907
[18]
LA Wu, AC Lapeyre 3rd, LT Cooper.
Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis.
Mayo Clin Proc, 76 (2001), pp. 1030-1038
[19]
CP Taliercio, BA Olney, JT Lie.
Myocarditis related to drug hypersensitivity.
Mayo Clin Proc, 60 (1985), pp. 463-468
[20]
M Ben m'rad, S Leclerc-Mercier, P Blanche, et al.
Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients.
Medicine (Baltimore), 88 (2009), pp. 131-140
[21]
SA Factor.
Pharmacology of atypical antipsychotics.
Clin Neuropharmacol, 25 (2002), pp. 153-157
[22]
S Abidi, SM Bhaskara.
From chlorpromazine to clozapine–antipsychotic adverse effects and the clinician's dilemma.
Can J Psychiatry, 48 (2003), pp. 749-755
[23]
HY Meltzer, L Alphs, AI Green, et al.
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Arch Gen Psychiatry, 60 (2003), pp. 82-91
[24]
EM Goldner, L Hsu, P Waraich, et al.
Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature.
Can J Psychiatry, 47 (2002), pp. 833-843
[25]
CH Hennekens, AR Hennekens, D Hollar, et al.
Schizophrenia and increased risks of cardiovascular disease.
Am Heart J, 150 (2005), pp. 1115-1121
[26]
J Wilk, SC Marcus, J West, et al.
Substance abuse and the management of medication nonadherence in schizophrenia.
J Nerv Ment Dis, 194 (2006), pp. 454-457
[27]
PB Mortensen, K Juel.
Mortality and causes of death in first admitted schizophrenic patients.
Br J Psychiatry, 163 (1993), pp. 183-189
[28]
U Osby, N Correia, L Brandt, et al.
Mortality and causes of death in schizophrenia in Stockholm county, Sweden.
Schizophr Res, 45 (2000), pp. 21-28
[29]
MD Drici, WX Wang, XK Liu, et al.
Prolongation of QT interval in isolated feline hearts by antipsychotic drugs.
J Clin Psychopharmacol, 18 (1998), pp. 477-481
[30]
AH Glassman.
Schizophrenia, antipsychotic drugs, and cardiovascular disease.
J Clin Psychiatry, 66 (2005), pp. 5-10
[31]
DB Allison, DE Casey.
Antipsychotic-induced weight gain: a review of the literature.
J Clin Psychiatry, 62 (2001), pp. 22-31
[32]
L Dixon, P Weiden, J Delahanty, et al.
Prevalence and correlates of diabetes in national schizophrenia samples.
Schizophr Bull, 26 (2000), pp. 903-912
[33]
JM Meyer.
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapinetreated inpatients: metabolic outcomes after 1 year.
J Clin Psychiatry, 63 (2002), pp. 425-433
[34]
AH Glassman, JT Bigger Jr.
Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
Am J Psychiatry, 158 (2001), pp. 1774-1782
[35]
JM Alvir, JA Lieberman, AZ Safferman, et al.
Clozapine-induced agranulocytosis: incidence and risk factors in the United States.
N Engl J Med, 329 (1993), pp. 162-167
[36]
JJ Layland, D Liew, DL Prior.
Clozapine-induced cardiotoxicity: a clinical update.
Med J Aust, 190 (2009), pp. 190-192
[37]
S Annamraju, B Sheitman, S Saik, et al.
Early recognition of clozapine-induced myocarditis.
J Clin Psychopharmacol, 27 (2007), pp. 479-483
[38]
L La Grenade, D Graham, A Trontell.
Myocarditis and cardiomyopathy associated with clozapine use in the United States.
N Engl J Med, 345 (2001), pp. 224-225
[39]
MD Drici, S Priori.
Cardiovascular risks of atypical antipsychotic drug treatment.
Pharmacoepidemiol Drug Saf, 16 (2007), pp. 882-890
[40]
JG Kilian, K Kerr, C Lawrence, et al.
Myocarditis and cardiomyopathy associated with clozapine.
Lancet, 354 (1999), pp. 1841-1845
[41]
DB Merrill, GW Dec, DC Goff.
Adverse cardiac effects associated with clozapine.
J Clin Psychopharmacol, 25 (2005), pp. 32-41

Conflictos de interés: Los autores manifiestan que no tienen conflictos de interés en este artículo.

Copyright © 2011. Asociación Colombiana de Psiquiatría
Article options